Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Hikma Pharmaceuticals Plc ADR (HKMPY)

Hikma Pharmaceuticals Plc ADR (HKMPY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow 17.65
  • Price/Book 6.06
Trade HKMPY with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Latest Earnings Date N/A
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
46.3090 +0.41%
on 04/03/24
48.9100 -4.93%
on 04/03/24
-1.3400 (-2.80%)
since 03/14/24
3-Month
46.3090 +0.41%
on 04/03/24
51.6500 -9.97%
on 02/20/24
-3.2500 (-6.53%)
since 01/12/24
52-Week
42.2300 +10.11%
on 11/16/23
56.6300 -17.89%
on 08/14/23
+1.8150 (+4.06%)
since 04/14/23

Most Recent Stories

More News
Hikma confirms that it has not signed a licensing agreement with Opiant Pharmaceuticals

/CNW/ -- Hikma Pharmaceuticals PLC (Hikma) confirms that it has not entered into any transaction with Opiant Pharmaceuticals, contrary to a PR Newswire...

HKMPY : 46.5000 (-1.34%)
Bio-Thera Solutions and Hikma Pharmaceuticals Announce Exclusive Commercialization and License Agreement for BAT2206 in the US, a Proposed Biosimilar Referencing Stelara® (ustekinumab)

Bio-Thera Solutions, Ltd. (688177.SH) and Hikma Pharmaceuticals PLC (LSE: HIK) today announced that they have entered into a commercialization and license agreement to commercialize BAT2206, a monoclonal...

HIK.LN : 1,854.000 (+2.26%)
HKMPY : 46.5000 (-1.34%)
Melinta Therapeutics and Hikma Sign Exclusive Licensing Agreement for Two Novel Anti-Infectives for the Middle East and North Africa Region

Melinta Therapeutics (Melinta) and Hikma Pharmaceuticals PLC (Hikma) today announced they have entered into an exclusive licensing agreement for Vabomere ® (meropenem and vaborbactam) and Orbactiv ®...

HIK.LN : 1,854.000 (+2.26%)
HKMPY : 46.5000 (-1.34%)
Sesen Bio Announces Partnership with Hikma Pharmaceuticals for the Commercialization of Vicineumâ„¢ in the Middle East and North Africa

Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, and Hikma Pharmaceuticals, a multi-national pharmaceutical...

SESN : 12.5760 (+7.29%)
HIK.LN : 1,854.000 (+2.26%)
HKMPY : 46.5000 (-1.34%)
Hikma and Arecor Expand Collaboration

LONDON, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Hikma Pharmaceuticals PLC (Hikma or the Group), the multinational pharmaceutical company, and Arecor Limited, the biopharmaceutical company advancing today's...

HIK.LN : 1,854.000 (+2.26%)
HKMPY : 46.5000 (-1.34%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Hikma Pharmaceuticals PLC was incorporated on September 8, 2005. The Company, together with its subsidiaries, is engaged in the development, manufacture and marketing of a broad range of generic and in-licensed pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms. Its...

See More

Key Turning Points

3rd Resistance Point 46.5000
2nd Resistance Point 46.5000
1st Resistance Point 46.5000
Last Price 46.5000
1st Support Level 46.5000
2nd Support Level 46.5000
3rd Support Level 46.5000

See More

52-Week High 56.6300
Fibonacci 61.8% 51.1292
Fibonacci 50% 49.4300
Fibonacci 38.2% 47.7308
Last Price 46.5000
52-Week Low 42.2300

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar